233 related articles for article (PubMed ID: 19756527)
1. Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-over study.
Drueke B; Baetz J; Boecker M; Moeller O; Hiemke C; Gründer G; Gauggel S
Psychopharmacology (Berl); 2009 Dec; 207(2):213-23. PubMed ID: 19756527
[TBL] [Abstract][Full Text] [Related]
2. The role of 5-HT1a and 5-HT2a receptors in attention and motor control: a mechanistic study in healthy volunteers.
Wingen M; Kuypers KP; Ramaekers JG
Psychopharmacology (Berl); 2007 Feb; 190(3):391-400. PubMed ID: 17124621
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Escitalopram on Central Serotonergic and Dopaminergic Systems in Patients with Cervical Dystonia, and Its Relationship with Clinical Treatment Effects: A Double-Blind Placebo-Controlled Trial.
Zoons E; Tijssen MAJ; Dreissen YEM; Smit M; Booij J
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32521736
[No Abstract] [Full Text] [Related]
4. Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study.
Windischberger C; Lanzenberger R; Holik A; Spindelegger C; Stein P; Moser U; Gerstl F; Fink M; Moser E; Kasper S
Neuroimage; 2010 Jan; 49(2):1161-70. PubMed ID: 19833214
[TBL] [Abstract][Full Text] [Related]
5. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.
Klein N; Sacher J; Geiss-Granadia T; Attarbaschi T; Mossaheb N; Lanzenberger R; Pötzi C; Holik A; Spindelegger C; Asenbaum S; Dudczak R; Tauscher J; Kasper S
Psychopharmacology (Berl); 2006 Oct; 188(3):263-72. PubMed ID: 16955282
[TBL] [Abstract][Full Text] [Related]
6. [Mechanisms of action of antidepressants: new data from Escitalopram].
Fabre V; Hamon M
Encephale; 2003; 29(3 Pt 1):259-65. PubMed ID: 12876551
[TBL] [Abstract][Full Text] [Related]
7. Divergent effects of increased serotonergic activity on psychophysiological parameters of human attention.
Oranje B; Jensen K; Wienberg M; Glenthøj BY
Int J Neuropsychopharmacol; 2008 Jun; 11(4):453-63. PubMed ID: 17971261
[TBL] [Abstract][Full Text] [Related]
8. Serotonergic modulation of response inhibition and re-engagement? Results of a study in healthy human volunteers.
Drueke B; Boecker M; Schlaegel S; Moeller O; Hiemke C; Gründer G; Gauggel S
Hum Psychopharmacol; 2010 Aug; 25(6):472-80. PubMed ID: 20737520
[TBL] [Abstract][Full Text] [Related]
9. Effects of escitalopram on attentional bias to cocaine-related stimuli and inhibitory control in cocaine-dependent subjects.
Liu S; Lane SD; Schmitz JM; Cunningham KA; John VP; Moeller FG
J Psychopharmacol; 2013 Sep; 27(9):801-7. PubMed ID: 23761390
[TBL] [Abstract][Full Text] [Related]
10. Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI.
Wingen M; Kuypers KP; Ramaekers JG
J Psychopharmacol; 2007 Jul; 21(5):477-85. PubMed ID: 17092965
[TBL] [Abstract][Full Text] [Related]
11. Sustained attention and serotonin: a pharmaco-fMRI study.
Wingen M; Kuypers KP; van de Ven V; Formisano E; Ramaekers JG
Hum Psychopharmacol; 2008 Apr; 23(3):221-30. PubMed ID: 18257001
[TBL] [Abstract][Full Text] [Related]
12. SSRI effects on pyschomotor performance: assessment of citalopram and escitalopram on normal subjects.
Paul MA; Gray GW; Love RJ; Lange M
Aviat Space Environ Med; 2007 Jul; 78(7):693-7. PubMed ID: 17679567
[TBL] [Abstract][Full Text] [Related]
13. Escitalopram effects on insula and amygdala BOLD activation during emotional processing.
Arce E; Simmons AN; Lovero KL; Stein MB; Paulus MP
Psychopharmacology (Berl); 2008 Mar; 196(4):661-72. PubMed ID: 18058090
[TBL] [Abstract][Full Text] [Related]
14. [Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].
Mnie-Filali O; El Mansari M; Scarna H; Zimmer L; Sánchez C; Haddjeri N
Encephale; 2007 Dec; 33(6):965-72. PubMed ID: 18789789
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses.
Nadeem HS; Attenburrow MJ; Cowen PJ
Neuropsychopharmacology; 2004 Sep; 29(9):1699-703. PubMed ID: 15127082
[TBL] [Abstract][Full Text] [Related]
16. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial.
Wingen M; Bothmer J; Langer S; Ramaekers JG
J Clin Psychiatry; 2005 Apr; 66(4):436-43. PubMed ID: 15816785
[TBL] [Abstract][Full Text] [Related]
17. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.
Wade A; Michael Lemming O; Bang Hedegaard K
Int Clin Psychopharmacol; 2002 May; 17(3):95-102. PubMed ID: 11981349
[TBL] [Abstract][Full Text] [Related]
18. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
Burke WJ; Gergel I; Bose A
J Clin Psychiatry; 2002 Apr; 63(4):331-6. PubMed ID: 12000207
[TBL] [Abstract][Full Text] [Related]
19. Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study.
Langley C; Armand S; Luo Q; Savulich G; Segerberg T; Søndergaard A; Pedersen EB; Svart N; Overgaard-Hansen O; Johansen A; Borgsted C; Cardinal RN; Robbins TW; Stenbæk DS; Knudsen GM; Sahakian BJ
Neuropsychopharmacology; 2023 Mar; 48(4):664-670. PubMed ID: 36683090
[TBL] [Abstract][Full Text] [Related]
20. Blunted autonomic reactivity to pharmacological panic challenge under long-term escitalopram treatment in healthy men.
Agorastos A; Kellner M; Stiedl O; Muhtz C; Wiedemann K; Demiralay C
Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25522396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
